# A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

> **NCT05624918** · PHASE2 · RECRUITING · sponsor: **Ashish Manne** · enrollment: 38 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma
- Resectable Pancreatic Cancer

## Interventions

- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine
- **DEVICE:** NovoTTF-200T(P)

## Key facts

- **NCT ID:** NCT05624918
- **Lead sponsor:** Ashish Manne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2027-08-29
- **Final completion:** 2028-08-29
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624918, "A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05624918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*